RxDoctor Payments Data

Julio Meza, MD

Family Medicine · Santa Monica, CANPI 1649666470

Payments from drug & device makers

$8,176in general payments, 2019–2025

Across 42 payments — averaging $194.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$7K
  • AbbVie$377
  • Braeburn Inc.$223
  • Vertex$104
  • Alkermes, Inc.$76
  • Catalyst Pharmaceuticals, Inc.$45
  • plus $83 from 4 others

What the payments were for

  • Speaking & faculty fees$5,85072%
  • Travel & lodging$1,02713%
  • Food & beverage$1,30016%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,176 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$71,882
Medicare patients
192
Services billed
598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine34$68,699
VivitrolNaltrexone Microspheres26$41,680
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl228$36,201
BelbucaBuprenorphine Hcl50$35,413
Buprenorphine92$28,378
RelistorMethylnaltrexone Bromide12$25,370
LinzessLinaclotide23$14,496
MovantikNaloxegol Oxalate21$13,573
Oxycodone Hcl241$5,404
Buprenorphine Hcl52$4,180
Fentanyl30$4,090
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen132$4,043
Lubiprostone25$3,332
Naltrexone Hcl40$2,194
Methocarbamol22$2,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade$7,268$68,69934 claims
Alkermes, Inc.Vivitrol$76$41,68026 claims
AbbVieLinzess$377$14,49623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →